Pharma Neutral 5

Sarepta Therapeutics Sees Surge in Call Options Following Rare Disease Data

· 3 min read · Verified by 2 sources · By Biotech Intelligence Brief Editorial
Share

Key Takeaways

  • Bullish options activity for Sarepta Therapeutics (SRPT) spiked on March 25, 2026, as the market reacted to promising early data for its RNA-based rare disease pipeline.
  • The increased trading volume coincides with the company’s strategic push for full FDA approval of its core Duchenne muscular dystrophy portfolio.

Mentioned

Sarepta Therapeutics company SRPT FDA organization Elevidys product

Key Intelligence

Key Facts

  1. 1Unusually large volume of call options purchased for SRPT on March 25, 2026.
  2. 2Early clinical data for FSHD and DM1 therapies reported as 'promising' by industry outlets.
  3. 3Sarepta plans to seek full FDA approval for its existing exon-skipping drug portfolio.
  4. 4Brokerages recently raised price targets following a period of stock underperformance.
  5. 5The company is pivoting to a 'rebound' strategy after a tumultuous 2025 fiscal year.
Options Market Sentiment

Analysis

Sarepta Therapeutics (NASDAQ: SRPT) experienced a significant surge in call option volume on March 25, 2026, signaling a sharp pivot in investor sentiment toward the biotechnology leader. This unusual trading activity, characterized by a high volume of bullish bets, follows a series of clinical and regulatory developments that suggest the company is emerging from a period of high volatility. The concentration of call buying indicates that institutional and retail traders are positioning for a sustained recovery, driven by both new clinical data and a maturing commercial portfolio.

The immediate catalyst for the options surge appears to be the release of early-stage clinical data regarding Sarepta’s RNA-based therapies for rare diseases, specifically Facioscapulohumeral Muscular Dystrophy (FSHD) and Myotonic Dystrophy Type 1 (DM1). Reports from STAT News and Endpoints News highlighted that these early readouts have provided a much-needed boost to the company’s pipeline credibility. After what industry analysts described as a 'tumultuous year' for the firm, these results offer a potential path forward beyond its primary focus on Duchenne Muscular Dystrophy (DMD). The market's reaction suggests that investors are beginning to value Sarepta’s broader RNA platform rather than viewing it solely through the lens of its lead gene therapy, Elevidys.

Sarepta Therapeutics (NASDAQ: SRPT) experienced a significant surge in call option volume on March 25, 2026, signaling a sharp pivot in investor sentiment toward the biotechnology leader.

Parallel to these clinical updates, Sarepta is making a strategic regulatory push that could significantly de-risk its current revenue streams. The company recently announced its intention to seek full FDA approval for its suite of exon-skipping drugs, which currently include Exondys 51, Vyondys 53, and Amondys 45. These therapies have been operating under accelerated approval pathways for several years. Transitioning to full approval would not only solidify their market position but also potentially ease long-term reimbursement hurdles with payers. This regulatory maturation is a critical component of the 'rebound' narrative that is currently attracting options traders.

What to Watch

From a market perspective, Sarepta has been categorized by some analysts as a 'beaten-down' stock that may finally be finding a floor. Recent brokerage actions support this view; while price targets remain varied, the trend has shifted toward upward revisions. For instance, recent target adjustments have ranged from conservative single digits to more optimistic mid-30s, reflecting a wide disparity in how analysts value the company’s long-term gene therapy royalties versus its immediate RNA pipeline. The high volume of call options suggests that the 'smart money' is betting on the higher end of these valuations as the company clears its upcoming regulatory hurdles.

Looking ahead, the primary milestones for investors to watch include the formal filing of the supplemental New Drug Applications (sNDAs) for full approval of the exon-skipping portfolio and more detailed data from the FSHD and DM1 programs. If Sarepta can maintain this clinical momentum, the current options activity may be the precursor to a broader institutional re-entry into the stock. However, the company remains sensitive to regulatory shifts and the competitive landscape in the DMD space, where rivals continue to develop next-generation gene therapies. For now, the options market is signaling that the risk-reward profile for Sarepta has tilted decidedly in favor of the bulls.

Timeline

Timeline

  1. SEC Filing

  2. Analyst Revisions

  3. Regulatory Strategy

  4. Options Surge

  5. Clinical Data Release

Sources

Sources

Based on 2 source articles

Cite This Page

"Sarepta Therapeutics Sees Surge in Call Options Following Rare Disease Data." Biotech Intelligence Brief, March 25, 2026. https://getbiobrief.com/story/sarepta-therapeutics-options-surge-rare-disease-data

Related Stories

Pharma

49-Year Species Rule Ends: Biotech’s Natural Drug Library Faces Extinction Risk

The U.S. Interior Department’s cancellation of automatic ESA protections for threatened species could accelerate biodiversity loss, directly threatening the natural sources of many pharmaceuticals. Bioprospecting and natural product R&D face heightened uncertainty as habitat destruction outpaces species discovery. The rule change adds regulatory complexity for biotech companies seeking access to rare organisms.

Pharma

Only 92 Deals: Big Pharma's TrumpRx Offering Covers Under 12% of Its 800+ Drug Stable

TrumpRx, the Trump administration's drug discount website, has secured voluntary pricing deals on only 92 brand-name drugs—less than 12% of the 800-plus products from 17 major pharmaceutical companies. High-cost therapies for inflammatory diseases, HIV, and cancer are largely excluded, raising doubts about industry's willingness to compromise on pricing without legislation.

Pharma

5,100 Suspected Cyclospora Cases Drive Demand for Rapid Diagnostics and New Therapies

The CDC's health alert on a cyclosporiasis outbreak with 5,100 suspected cases presents urgent needs in the biotech sector for rapid diagnostics, antiparasitic drug development, and food safety technologies. The parasite Cyclospora cayetanensis, with its long incubation period, challenges traditional detection methods, while treatment relies on a decades-old antibiotic. Innovators could capitalize on multiplex PCR panels and next-generation sequencing for outbreak tracking.

Pharma

Novartis, Roche Face 50% PBS Price Cut on MS Drugs as Briumvi Triggers Review

A July 2026 Australian PBS review for Roche's Ocrevus and Novartis’s Kesimpta could reduce government reimbursement by up to 50%, triggered by reference pricing with new low-cost entrant Briumvi. Manufacturers risk margin erosion or market withdrawal.

How we covered this story

Every story in our biotech coverage is assembled from multiple primary sources, cross-referenced for factual consistency, and scored along three independent dimensions: sentiment, operational impact, and source-cluster confidence. Single-source rumors and unverifiable claims do not pass our editorial gate. When a story shows "Verified by N sources" with N≥2, the development is independently corroborated; when N=1, we mark it explicitly so readers can weigh the signal accordingly.

Impact scoring uses a 1-10 scale weighted toward regulatory, financial, and operational consequence rather than coverage volume. A topic that runs in every outlet but moves no real decisions ranks lower than a niche regulatory filing that reshapes how operators in the biotech space have to behave. Read our full methodology for the scoring rubric, our glossary for term definitions, and our trends index for the longitudinal view across the beat.

Signal on this pageWhat it tells you
Verified by N sourcesIndependent corroboration count. N≥2 is our confidence floor; N=1 is marked explicitly.
Impact score (1-10)Regulatory + financial + operational weight. 8+ signals an experienced-operator action item.
SentimentFive-tier classification trained on labeled biotech-specific corpora.
TimelineWhere applicable, the related-events sequence that contextualizes today's development.